• Veru posted fiscal 2026 Q2 net loss of $2.7 million, or $0.12 per share, narrowing from $7.9 million, or $0.54 per share, a year earlier.
• Operating loss improved to $7.2 million from $8.1 million, while R&D expense fell to $3.1 million from $3.9 million.
• G&A expense dropped to $4.1 million from $5.2 million; cash, cash equivalents and restricted cash rose to $27.6 million at March 31 from $15.8 million at Sept. 30.
• Phase 2b PLATEAU trial of enobosarm 3 mg with semaglutide in about 200 older patients with obesity was actively enrolling, with interim DXA data expected in Q1 2027 and final topline results expected in Q4 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130630PRIMZONEFULLFEED9718600) on May 13, 2026, and is solely responsible for the information contained therein.